Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026

CAMBRIDGE, MA / ACCESS Newswire / September 21, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced that three abstracts on intismeran autogene, an investigational mRNA-based individualized neoantigen therapy, have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2026, which will be held October 23-27 in Madrid, Spain.

Presidential Symposium: * LBA1- INTerpath-001: Phase 3 study of the mRNA-based individualized neoantigen therapy (INT) intismeran autogene (intismeran) plus pembrolizumab (pembro) vs pembro alone for adjuvant treatment of resected stage IIB-IV melanoma (MEL) Session Type/Title: Presidential Symposium Date & Time: Saturday, October 24, 4:30 PM CEST / 10:30 AM EDT Presenter: Georgina V. Long (Sydney, Australia, NSW) Poster Presentations: * Abstract 3151P: Adjuvant intismeran autogene plus FOLFIRINOX in resectable pancreatic ductal adenocarcinoma: results from a phase I study Session Type/Title: Poster - Pancreatic cancer Date & Time: Sunday, October 25, 12:00-12:45 PM CET Presenter: David J. Pinato (London, United Kingdom) * Abstract 2550TiP: INTerpath-014: A Phase 3 Study of Adjuvant Intismeran Autogene (Intismeran) Plus Subcutaneous Pembrolizumab (Pembro SC) or Intismeran Monotherapy vs Placebo in Completely Resected High-Risk Stage I NSCLC Session Type/Title: Poster - NSCLC, early stage Date & Time: Monday, October 26, 12:00-12:45 PM CET Presenter: Charu Aggarwal (Philadelphia, United States of America) Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada.